Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Trial purpose
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
|
national trial reference number | NCT05714085 |
|
Conditions |
Heart Failure, Left Ventricular Systolic Dysfunction
|
|
Age Range | 29 Days - 17 Years (Child) |
|
Sex | All |
|
Current trial phase | 2, 3 |
|
Trial start and end dates |
05-31-2023 04-15-2032 |
Trial locations (0)
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.